CETP and Alzheimer disease: Similarly, secondary analysis of residual plasma specimens from CETP inhibitor trials could reveal whether AD-relevant biomarkers such as Aβ42:Aβ40, p-tau-181, p-tau-217, neurofilament light, and glial fibrillary acidic protein are altered after exposure to CETP inhibition and whether the degree of biomarker change correlates with the extent of LDL lowering and/or HDL elevation.